# Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Source: https://onco.cc/trials/nct02678572/  
OnCo record `nct02678572` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Percutaneous hepatic perfusion in Uveal melanoma, run by Delcath Systems Inc., completed.

## Summary

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma is a phase 3 interventional study registered as NCT02678572 by Delcath Systems Inc., with 102 participants recorded, started 2016-02-01 and reaching its primary completion in 2023-05-18. Interventions recorded: Melphalan/HDS. Conditions recorded: Ocular Melanoma, Uveal Melanoma.

Linked to the technology Percutaneous hepatic perfusion because the registry's title names it ("percutaneous hepatic perfusion") and Uveal melanoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02678572
- Phase: 3
- Setting: A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
- Sponsor: Delcath Systems Inc.
- Enrolled: 102

## Sources

- ClinicalTrials.gov NCT02678572: https://clinicaltrials.gov/study/NCT02678572

## Connected records

- cancers: [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- technologies: [Percutaneous hepatic perfusion (chemosaturation)](https://onco.cc/technologies/percutaneous-hepatic-perfusion/)
- drugs: [Melphalan (including hepatic delivery system)](https://onco.cc/drugs/melphalan/)
- companies: [Delcath Systems](https://onco.cc/companies/delcath/)

---
JSON: https://onco.cc/api/v1/entities/nct02678572.json